Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

The mutant JAK2V617F tyrosine kinase (TK) is present in the majority of patients with BCR-ABL–negative myeloproliferative neoplasms (MPNs). JAK2V617F activates downstream signaling through the signal transducers and activators of transcription (STAT), RAS/mitogen-activated protein kinase (MAPK), and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wang, Yongchao, Fiskus, Warren, Chong, Daniel G., Buckley, Kathleen M., Natarajan, Kavita, Rao, Rekha, Joshi, Atul, Balusu, Ramesh, Koul, Sanjay, Chen, Jianguang, Savoie, Andrew, Ustun, Celalettin, Jillella, Anand P., Atadja, Peter, Levine, Ross L., Bhalla, Kapil N.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2009
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2788976/
https://ncbi.nlm.nih.gov/pubmed/19828702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-05-222133
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados